Search company, investor...


Founded Year



Dead | Dead

Total Raised


About Cebix

Cebix is developing Ersatta, a disease-modifying replacement peptide for the treatment of complications associated with diabetes. Ersatta is a long-acting form of C-peptide that, unlike other products simply directed at symptomatic relief, has the potential to reverse the chronic complications of diabetes.

Headquarters Location

12520 High Bluff Drive Suite 380

San Diego, California, 92130,

United States


Missing: Cebix's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Cebix's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Cebix

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Cebix is included in 1 Expert Collection, including Diabetes.



1,903 items

Cebix Patents

Cebix has filed 10 patents.

patents chart

Application Date

Grant Date


Related Topics




Diabetes, Insulin therapies, Human proteins, Peptide hormones, Clusters of differentiation


Application Date


Grant Date



Related Topics

Diabetes, Insulin therapies, Human proteins, Peptide hormones, Clusters of differentiation



Latest Cebix News

Cebix hangs it up after raising $50M for diabetes drug

Feb 24, 2015

Reprint La Jolla, CA's Cebix has quietly closed up shop, Xconomy reports, after its once-promising diabetes candidate failed to hit the mark in Phase IIb. Last anyone heard from Cebix, it was powering into a mid-stage test of Ersatta, which is an analog of the body's natural C peptide hormone designed to combat loss of nerve function tied to Type 1 diabetes. The drug performed well in a Phase I/II bridge study, and, in 2012, Cebix embarked on a 250-patient Phase IIb efficacy trial to test how well Ersatta could improve nerve function compared to placebo, according to . That study wrapped up in December, and Cebix concluded that "Ersatta and placebo were, alas, indistinguishable," CEO Joel Martin told Xconomy. Seeing little reason to press on, the company promptly disbanded, winding down in its operations in about 30 days, Martin said. Cebix had raised nearly $50 million on its way into the failed Phase IIb, drawing the support of InterWest, Sofinnova Ventures and Thomas, McNerney & Partners. And, counting on Ersatta's success, last year the company started putting together a $35 million new round to pay its way toward late-stage studies, according to an SEC filing . Instead, Martin and his team are now out scouting for new startup opportunities, he said. Targeting C peptide to treat diabetes has something of a checkered clinical history. Tolerx , alongside partner GlaxoSmithKline ( $GSK ), developed an antibody designed to boost levels of the hormone but bombed out in Phase III, and the biotech met a fate similar to Cebix's in 2011. And teplizumab, another antibody crafted to preserve C peptide, came up short for Eli Lilly ( $LLY ) in a Phase III study, but its biotech partner, MacroGenics ( $MGNX ), has since revived the program and found some success in early-stage diabetics. - read the Xconomy story

Cebix Frequently Asked Questions (FAQ)

  • When was Cebix founded?

    Cebix was founded in 2008.

  • Where is Cebix's headquarters?

    Cebix's headquarters is located at 12520 High Bluff Drive, San Diego.

  • What is Cebix's latest funding round?

    Cebix's latest funding round is Dead.

  • How much did Cebix raise?

    Cebix raised a total of $59.89M.

  • Who are the investors of Cebix?

    Investors of Cebix include Sofinnova Ventures, InterWest Partners, Thomas McNerney & Partners, HealthCap Venture Capital and Qualifying Therapeutic Discovery Project.

  • Who are Cebix's competitors?

    Competitors of Cebix include ISTO Technologies, Immunservice, Arcion Therapeutics, Pharmasset, NanoCor Therapeutics and 10 more.

Compare Cebix to Competitors


RhinoCyte is a biotechnology company that has developed a method of isolating adult stem cells located in the olfactory regions of the mucosal lining of the human nasal passageway, which can be used in therapies for spinal cord injury, multiple sclerosis, ALS and Parkinson's Disease.


Spaltudaq Corporation, a privately-held biotechnology company based in Seattle, is focused on developing therapeutic antibodies for the treatment of inflammation, infectious disease and cancer. Our technology harnesses the power of the human immune system to identify tumor-specific or pathogen-specific monoclonal antibodies from human tissue samples.

Aderans Research Institute

ARI is developing biotechnology solutions to the pervasive problem of hair loss. This cell therapy and tissue engineering research focuses on developing hair follicle progenator tissue for cosmetic hair replacement surgery. Safe and effective tissue engineered products will be developed based upon the molecular and cellular mechanisms of hair growth and multiplicati. ARI was created by Aderans Co., of Tokyo, Japan and its US Susidiary Bosley, the World's largest hair restoration practice. The company was formerly known as BioAmide .

NanoCor Therapeutics

NanoCor Therapeutics is a biotechnology company founded to create a viable intracellular genetic protein therapy for the treatment of Chronic Heart Failure (CHF)


BioRegenix is a biotechnology company committed to the development of tissue regeneration technology.

Cellular Engineering Technologies

Cellular Engineering Technologies is a biotechnology tissue engineering company.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.